| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2022 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONFIDENTIAL | 24 | Q2 2023 | 0.0% |
| Celldex Therapeutics, Inc. | 9 | Q4 2018 | 100.0% |
| HYATT | 2 | Q4 2013 | 100.0% |
| GELESIS HLDGS INC | 1 | Q1 2023 | 100.0% |
View KLP Enterprises, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Celldex Therapeutics, Inc. | December 09, 2016 | 6,865,006 | 5.7% |
View KLP Enterprises, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-15 |
| 13F-HR | 2023-08-15 |
| 13F-HR | 2023-05-15 |
| 13F-NT | 2023-02-14 |
| 13F-NT | 2022-11-14 |
| 13F-NT | 2022-08-01 |
| 13F-NT | 2022-05-09 |
| 13F-NT | 2022-02-08 |
| 3 | 2022-01-21 |
View KLP Enterprises, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.